LMAT on Nasdaq
LEMAITRE VASCULAR INC
We are a global provider of medical devices and human tissue cryopreservation services largely used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular.4 From its latest annual report
$83.86 up 1.24 (1.50%)Price as of Oct 15, 2026 at 17:33 UTC
Last updated Oct 19, 2026.
Overview
Compare with ORTHOPEDIATRICS CORP, CERUS CORP or TREACE MEDICAL CONCEPTS, INC., or pick any stock.
- TickerLMAT on Nasdaq1
- IndustrySurgical & Medical Instruments & Apparatus1
- HeadquartersBurlington, Massachusetts1
- Business address63 Second Avenue, Burlington, Ma 018033
- Filer categoryLarge accelerated filer3
See how the biggest companies compare on our leaderboards
We are a global provider of medical devices and human tissue cryopreservation services largely used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. We develop, manufacture, and market vascular devices to address the needs of vascular surgeons and, to a lesser degree, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Our diversified portfolio of devices consists of brand name products that are used in arteries and veins and are well known to vascular surgeons. Our principal product offerings are sold globally, primarily in the United States, Europe, Canada and Asia Pacific. We estimate that the annual worldwide market for peripheral vascular devices exceeds $9 billion, within which we estimate that the market for our products is approximately $1 billion.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
71.5%Gross margin5
27.2%Operating margin5
23.1%Net margin5
13.5%Revenue growth, 20255
14.7%Return on equity5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Regions
United States brought in 42% of the revenue LEMAITRE VASCULAR INC broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $117.8M | $128.7M | $141.6M |
| EMEA | $51.1M | $60.0M | $73.1M |
| Other Countries | $42.9M | $52.1M | $61.7M |
| Germany | $13.4M | $14.4M | $17.9M |
| Asia Pacific | $12.1M | $15.3M | $16.8M |
| Canada | $10.8M | $13.7M | $15.3M |
| United Kingdom | $8.6M | $11.0M | $13.2M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue28¢$71.1M
- Research and development6¢$14.1M
- Other costs34¢$84.0M
- Interest2¢$5.2M
- Income tax7¢$17.4M
- Profit23¢$57.7M
Out of $249.6M in revenue.5
Where each dollar of operating cash went, fiscal 2025
- Dividends paid22¢$18.1M
- Share buybacks2¢$1.8M
- Kept or used elsewhere75¢$61.3M
Out of $81.3M of cash from operations.5
Financial statements
Every line of the income statement as filed: the last 4 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net sales | $249.6M | $219.9M | $193.5M | |
| Cost of sales | $71.1M | $69.0M | $66.4M | |
| Gross profit | $178.5M | $150.9M | $127.0M | |
| Sales and marketing | $54.5M | $46.7M | $41.1M | |
| General and administrative | $42.0M | $36.3M | $31.8M | |
| Research and development | $14.1M | $15.7M | $17.0M | |
| Restructuring | $0 | $0 | $485.0K | $3.1M |
| Total operating expenses | $110.6M | $98.6M | $90.3M | |
| Income from operations | $67.9M | $52.3M | $36.7M | |
| Investment income | $13.1M | $4.9M | $3.1M | |
| Interest expense | -$5.2M | -$205.0K | ||
| Other income (loss), net | -$638.0K | -$125.0K | -$314.0K | |
| Income before income taxes | $75.2M | $56.9M | $39.5M | |
| Provision for income taxes | $17.4M | $12.8M | $9.4M | |
| Net income | $57.7M | $44.0M | $30.1M | |
| Basic (in dollars per share) | $2.55 | $1.96 | $1.36 | |
| Diluted (in dollars per share) | $2.52 | $1.93 | $1.34 | |
| Basic (in shares) | 22.6M shares | 22.5M shares | 22.2M shares | |
| Diluted (in shares) | 22.9M shares | 22.8M shares | 22.4M shares | |
| Cash dividends declared per common share (in dollars per share) | $0.80 | $0.64 | $0.56 |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $28.2M | $25.6M | ||
| Short-term marketable securities | $330.9M | $274.1M | ||
| Accounts receivable, net of allowances of $1,400 at December 31, 2025 and $1,369 at December 31, 2024 | $33.6M | $30.1M | ||
| Inventory and other deferred costs | $70.4M | $64.9M | ||
| Prepaid expenses and other current assets | $5.1M | $7.5M | ||
| Total current assets | $468.2M | $402.2M | ||
| Property and equipment, net | $27.0M | $24.8M | ||
| Right-of-use leased assets | $15.8M | $16.8M | ||
| Goodwill | $65.9M | $65.9M | ||
| Other intangibles, net | $33.1M | $35.8M | ||
| Deferred tax assets | $759.0K | $1.4M | ||
| Other assets | $4.9M | $4.9M | ||
| Total assets | $615.7M | $551.8M | ||
| Accounts payable | $3.6M | $1.8M | ||
| Accrued expenses | $29.4M | $24.7M | ||
| Acquisition-related obligations | $322.0K | $1.4M | ||
| Lease liabilities - short-term | $2.9M | $2.7M | ||
| Total current liabilities | $36.3M | $30.6M | ||
| Convertible senior notes, net | $168.6M | $167.8M | ||
| Lease liabilities - long-term | $14.0M | $15.2M | ||
| Deferred tax liabilities | $1.7M | $85.0K | ||
| Other long-term liabilities | $1.5M | $831.0K | ||
| Total liabilities | $222.2M | $214.5M | ||
| Common stock, $0.01 par value; 37,000,000 shares authorized, 24,396,904 and 24,153,165 shares issued, 22,772,607 and 22,549,340 shares outstanding, respectively | $244.0K | $242.0K | ||
| Additional paid-in capital | $228.4M | $213.8M | ||
| Retained earnings | $184.7M | $145.1M | ||
| Accumulated other comprehensive loss | -$2.4M | -$6.2M | ||
| Treasury stock, at cost; 1,624,297 and 1,603,825 shares, respectively | -$17.4M | -$15.6M | ||
| Total stockholders equity | $393.5M | $337.3M | $297.9M | $268.2M |
| Total liabilities and stockholders equity | $615.7M | $551.8M | ||
| Accounts Receivable, Allowance for Credit Loss, Current | $1.4M | $1.4M | ||
| Preferred stock, par value | $0.01 | $0.01 | ||
| Preferred Stock, Shares Authorized | 3.0M shares | 3.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.01 | $0.01 | ||
| Common Stock, Shares Authorized | 37.0M shares | 37.0M shares | ||
| Common Stock, Shares, Issued | 24.4M shares | 24.2M shares | ||
| Common stock, shares, outstanding | 22.8M shares | 22.5M shares | ||
| Treasury Stock, Common, Shares | 1.6M shares | 1.6M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $28.2M | $25.6M | ||
| Short-term marketable securities | $330.9M | $274.1M | ||
| Accounts receivable, net of allowances of $1,400 at December 31, 2025 and $1,369 at December 31, 2024 | $33.6M | $30.1M | ||
| Inventory and other deferred costs | $70.4M | $64.9M | ||
| Prepaid expenses and other current assets | $5.1M | $7.5M | ||
| Total current assets | $468.2M | $402.2M | ||
| Property and equipment, net | $27.0M | $24.8M | ||
| Right-of-use leased assets | $15.8M | $16.8M | ||
| Goodwill | $65.9M | $65.9M | ||
| Other intangibles, net | $33.1M | $35.8M | ||
| Deferred tax assets | $759.0K | $1.4M | ||
| Other assets | $4.9M | $4.9M | ||
| Total assets | $615.7M | $551.8M | ||
| Accounts payable | $3.6M | $1.8M | ||
| Accrued expenses | $29.4M | $24.7M | ||
| Acquisition-related obligations | $322.0K | $1.4M | ||
| Lease liabilities - short-term | $2.9M | $2.7M | ||
| Total current liabilities | $36.3M | $30.6M | ||
| Convertible senior notes, net | $168.6M | $167.8M | ||
| Lease liabilities - long-term | $14.0M | $15.2M | ||
| Deferred tax liabilities | $1.7M | $85.0K | ||
| Other long-term liabilities | $1.5M | $831.0K | ||
| Total liabilities | $222.2M | $214.5M | ||
| Common stock, $0.01 par value; 37,000,000 shares authorized, 24,396,904 and 24,153,165 shares issued, 22,772,607 and 22,549,340 shares outstanding, respectively | $244.0K | $242.0K | ||
| Additional paid-in capital | $228.4M | $213.8M | ||
| Retained earnings | $184.7M | $145.1M | ||
| Accumulated other comprehensive loss | -$2.4M | -$6.2M | ||
| Treasury stock, at cost; 1,624,297 and 1,603,825 shares, respectively | -$17.4M | -$15.6M | ||
| Total stockholders equity | $393.5M | $337.3M | $297.9M | $268.2M |
| Total liabilities and stockholders equity | $615.7M | $551.8M | ||
| Accounts Receivable, Allowance for Credit Loss, Current | $1.4M | $1.4M | ||
| Preferred stock, par value | $0.01 | $0.01 | ||
| Preferred Stock, Shares Authorized | 3.0M shares | 3.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.01 | $0.01 | ||
| Common Stock, Shares Authorized | 37.0M shares | 37.0M shares | ||
| Common Stock, Shares, Issued | 24.4M shares | 24.2M shares | ||
| Common stock, shares, outstanding | 22.8M shares | 22.5M shares | ||
| Treasury Stock, Common, Shares | 1.6M shares | 1.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income | $57.7M | $44.0M | $30.1M |
| Depreciation and amortization | $10.4M | $9.6M | $9.5M |
| Stock-based compensation | $7.8M | $6.6M | $5.3M |
| Amortization of issuance costs on convertible senior notes | $873.0K | $62.0K | $0 |
| Provision for inventory write-downs | $2.7M | $3.1M | $2.2M |
| Provision (benefit) for deferred income taxes | $2.3M | -$451.0K | $783.0K |
| Loss on divestitures | $0 | $0 | $485.0K |
| Provision for credit losses | $817.0K | $813.0K | $344.0K |
| Unrealized loss on equity investments | $535.0K | $0 | $0 |
| Fair value adjustments to contingent consideration obligations | $134.0K | -$78.0K | |
| Foreign currency transaction effect on income | -$176.0K | $362.0K | -$705.0K |
| Accounts receivable | -$2.9M | -$6.4M | -$3.1M |
| Inventory and other deferred costs | -$7.2M | -$10.6M | -$9.8M |
| Prepaid expenses and other assets | $2.4M | -$2.3M | -$2.9M |
| Accounts payable and other liabilities | $4.2M | -$923.0K | $4.6M |
| Accrued interest | $1.8M | $144.0K | $0 |
| Net cash provided by operating activities | $81.3M | $44.1M | $36.8M |
| Purchases of short-term marketable securities | -$641.3M | -$277.9M | -$16.6M |
| Purchases of property and equipment | -$6.8M | -$7.0M | -$7.3M |
| Payments related to acquisitions, net of cash acquired | -$1.9M | $0 | -$899.0K |
| Proceeds from sales of short-term marketable securities | $585.1M | $84.8M | $0 |
| Net cash used in investing activities | -$64.9M | -$200.1M | -$24.7M |
| Proceeds from issuance of convertible senior notes, net of issuance costs paid of $3,234 | $0 | $169.3M | $0 |
| Costs paid related to issuance of convertible senior notes | -$3.2M | ||
| Common stock cash dividend paid | -$18.1M | -$14.4M | -$12.4M |
| Proceeds from stock option exercises | $6.8M | $6.4M | $6.2M |
| Payment of withholding taxes in connection with net settlement of equity awards | -$1.8M | -$1.7M | -$853.0K |
| Deferred payments for acquisitions | -$1.4M | $0 | $0 |
| Net cash (used in) provided by financing activities | -$14.5M | $158.1M | -$7.1M |
| Effect of exchange rate changes on cash and cash equivalents | $864.0K | -$765.0K | $230.0K |
| Net increase in cash and cash equivalents | $2.6M | $1.3M | $5.1M |
No quarter-by-quarter statement was filed.
Leadership
Who has led LEMAITRE VASCULAR INC, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
2010201520202025
- Chief executive officerGeorge W. Lemaitre Oct 18, 2006 to now13
- ChairGeorge W. Lemaitre Oct 18, 2006 to now13
- PresidentDavid B. Roberts Mar 6, 2008 to now14
- PresidentGeorge W. Lemaitre Oct 18, 2006 to Mar 5, 200713
- PresidentPeter R. Gebauer Oct 18, 2006 to Sep 11, 201715
- Chief financial officerDorian Paul Leblanc Mar 21, 2025 to now16
- Chief financial officerJoseph P. Pellegrino Jr. Mar 6, 2008 to Mar 4, 202517
- Chief financial officerDavid B. Roberts Oct 18, 2006 to Jul 20, 200718
Board members and other officers (24)
- VP of Sales, The AmericasMichael T. Wijas Aug 28, 2015 to Jun 12, 201719
- VP, North American SalesRobert Linden V. Apr 29, 2008 to Jul 29, 201420
- V.P., Human Resources,DirectorCornelia W. Lemaitre Oct 18, 2006 to Jun 27, 201421
- V.P. Information TechnologyJonathan W. Ngau Oct 18, 2006 to Dec 22, 200622
- Executive V.P. FinanceJoseph P. Pellegrino Jr. Oct 18, 2006 to Jul 20, 200723
- V. P. North American SalesKevin D. Kelly Oct 18, 2006 to Mar 5, 200824
- Vice President, MarketingKimberly L. Cieslak Oct 18, 2006 to Mar 1, 200725
- V.P. Central European SalesMaik D. Helmers Oct 18, 2006 to Dec 22, 200626
- Director - R&DRyan H. Connelly Oct 18, 2006 to Nov 22, 200627
- Senior V. P., OperationsTrent G. Kamke Oct 18, 2006 to now28
- Board memberMartha Shadan Sep 23, 2022 to now29
- Board memberBridget A. Ross May 8, 2020 to now30
- Board memberJoseph P. Pellegrino Jr. Dec 7, 2016 to now31
- Board memberRussell D. Hays Jan 10, 2008 to Mar 10, 201432
- Board memberWilliam N. Thorndike Jr. Jun 20, 2008 to Jul 26, 201333
- Board memberCornelia W. Lemaitre Oct 18, 2006 to Aug 22, 201621
- Board memberDavid B. Roberts Oct 18, 2006 to now18
- Board memberDavid N. Gill Oct 18, 2006 to Jul 20, 200734
- Board memberDuane M. Desisto Oct 18, 2006 to Jul 20, 200735
- Board memberGeorge D. Lemaitre Oct 18, 2006 to Sep 5, 201236
- Board memberGuido J. Neels Oct 18, 2006 to Dec 22, 200637
- Board memberLawrence J. Jasinski Oct 18, 2006 to now38
- Board memberRyan H. Connelly Dec 22, 2006 to Dec 22, 200639
- General counselAaron M. Grossman Oct 18, 2006 to Sep 6, 201140
Timeline
- Oct 18, 2006New chief executive George W. Lemaitre becomes CEO13
Filings
568 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 35 major events, 424 insider forms, 28 large holders, 61 other. The latest 20:
- Oct 15, 20268-K EDGAR
- Sep 8, 20264 EDGAR
- Sep 8, 20264 EDGAR
- Sep 8, 20264 EDGAR
- Sep 8, 20264 EDGAR
- Sep 8, 20264 EDGAR
- Sep 8, 20264 EDGAR
- Sep 8, 20264 EDGAR
- Sep 8, 20264 EDGAR
- Sep 8, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Aug 5, 202610-Q EDGAR
- Aug 4, 20268-K EDGAR
- Jul 29, 2026144 EDGAR
- Jul 27, 2026SCHEDULE 13G EDGAR
- Jun 5, 20264 EDGAR
- Jun 5, 20264 EDGAR
- Jun 5, 20264 EDGAR
- Jun 5, 20264 EDGAR
- Jun 5, 20264 EDGAR
The 568 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
74 open-market trades by officers, directors and large owners since October 2021: 0 buys and 74 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 8, 2026 | LeMaitre George WChairman and CEO | Sale | 27,881 | $108.69 | $3.0M | Form 4 |
| May 8, 2026 | Kamke Trent GSenior V. P., Operations | Sale | 2,928 | $107.00 | $313.3K | Form 4 |
| May 7, 2026 | LeMaitre George WChairman and CEO | Sale | 18,600 | $107.64 | $2.0M | Form 4 |
| May 7, 2026 | Ross Bridget ADirector | Sale | 5,044 | $111.10 | $560.4K | Form 4 |
| May 7, 2026 | Jasinski Lawrence JDirector | Sale | 3,943 | $110.00 | $433.7K | Form 4 |
| Mar 11, 2026 | Kamke Trent GSenior V. P., Operations | Sale | 2,625 | $108.50 | $284.8K | Form 4 |
| Mar 11, 2026 | Roberts David BPresident and Director | Sale | 3,312 | $107.68 | $356.6K | Form 4 |
| Mar 2, 2026 | LeMaitre George WChairman and CEO | Sale | 55,930 | $107.81 | $6.0M | Form 4 |
| Feb 27, 2026 | Kamke Trent GSenior V. P., Operations | Sale | 1,044 | $110.29 | $115.1K | Form 4 |
| Feb 27, 2026 | Roberts David BPresident and Director | Sale | 8,464 | $106.80 | $904.0K | Form 4 |
| Feb 26, 2026 | LeMaitre George WChairman and CEO | Sale | 150,000 | $106.76 | $16.0M | Form 4 |
| Aug 12, 2025 | Jasinski Lawrence JDirector | Sale | 976 | $92.78 | $90.6K | Form 4 |
| Aug 11, 2025 | Roberts David BPresident and Director | Sale | 10,815 | $92.38 | $999.1K | Form 4 |
| Aug 11, 2025 | Roush John ADirector | Sale | 6,561 | $92.55 | $607.2K | Form 4 |
| Aug 8, 2025 | Ross Bridget ADirector | Sale | 2,500 | $94.00 | $235.0K | Form 4 |
| Aug 8, 2025 | Roush John ADirector | Sale | 939 | $93.49 | $87.8K | Form 4 |
| Aug 6, 2025 | LeMaitre George WChairman and CEO | Sale | 100,000 | $93.51 | $9.4M | Form 4 |
| May 20, 2025 | LeMaitre George WChairman and CEO | Sale | 4,399 | $85.10 | $374.4K | Form 4 |
| May 19, 2025 | LeMaitre George WChairman and CEO | Sale | 76,868 | $85.79 | $6.6M | Form 4 |
| May 16, 2025 | LeMaitre George WChairman and CEO | Sale | 18,733 | $84.77 | $1.6M | Form 4 |
All 74 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- FIRST TRUST PORTFOLIOS LPSCHEDULE 13G, 1 filing Jul 27, 202641
- George W. LemaitreSCHEDULE 13G/A, 6 filings Feb 11, 2022 to May 14, 202642
- VANGUARD GROUP INCSCHEDULE 13G/A, 4 filings Feb 10, 2022 to Mar 27, 202643
- Conestoga Capital Advisors, LLCSCHEDULE 13G/A, 5 filings Jan 10, 2022 to Jan 9, 202644
- BlackRockSCHEDULE 13G/A, 3 filings Oct 18, 2024 to Feb 5, 202545
- Copeland Capital Management, LLCSCHEDULE 13G, 5 filings Jan 26, 2022 to Jan 24, 202546
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 3,272,973 | $314.1M | 0.0% | +128,822 |
| Conestoga Capital Advisors, LLC | 1,367,513 | $131.2M | 2.9% | −109,300 |
| First Trust Advisors LP | 1,093,502 | $104.9M | 0.1% | +95,431 |
| Congress Asset Management Co | 963,706 | $92.5M | 0.6% | +129,177 |
| Vanguard Capital Management LLC | 953,437 | $91.5M | 0.0% | +41,379 |
| State Street Corp | 901,416 | $86.5M | 0.0% | +45,632 |
| Copeland Capital Management, LLC | 839,463 | $80.6M | 1.7% | −31,229 |
| Geode Capital Management, LLC | 788,835 | $75.7M | 0.0% | +130,390 |
| Vanguard Portfolio Management LLC | 604,833 | $58.0M | 0.0% | +42,063 |
| Geneva Capital Management LLC | 589,064 | $56.5M | 1.3% | −164,928 |
| Dimensional Fund Advisors LP | 493,889 | $47.4M | 0.0% | +17,554 |
| Goldman Sachs Group Inc | 473,194 | $45.4M | 0.0% | +40,778 |
| Invesco Ltd. | 448,389 | $43.0M | 0.0% | +114,412 |
| Morgan Stanley | 351,083 | $33.7M | 0.0% | −56,688 |
| Northern Trust Corp | 333,325 | $32.0M | 0.0% | +20,770 |
| Two Sigma Investments, LP | 316,528 | $30.4M | 0.0% | +34,550 |
| Royal Bank Of Canada | 308,765 | $29.6M | 0.0% | +36,111 |
| Annex Advisory Services, LLC | 248,253 | $23.8M | 0.4% | −2,357 |
| UBS Group AG | 247,804 | $23.8M | 0.0% | +206,387 |
| Envestnet Asset Management Inc | 244,729 | $23.5M | 0.0% | −29,667 |
| Kennedy Capital Management LLC | 228,934 | $22.0M | 0.4% | −7,843 |
| Kayne Anderson Rudnick Investment Management LLC | 220,497 | $21.2M | 0.1% | −10,221 |
| Ranger Investment Management, L.P. | 219,307 | $21.0M | 1.3% | −19,053 |
| Sei Investments Co | 206,764 | $19.8M | 0.0% | +70,090 |
| Charles Schwab Investment Management Inc | 206,279 | $19.8M | 0.0% | +8,304 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2Yahoo FinanceLMAT quote
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14SEC EDGARDavid B. Roberts, President
- 15SEC EDGARPeter R. Gebauer, President
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27SEC EDGARRyan H. Connelly, Director - R&D
- 28
- 29SEC EDGARMartha Shadan, Board member
- 30SEC EDGARBridget A. Ross, Board member
- 31
- 32SEC EDGARRussell D. Hays, Board member
- 33
- 34SEC EDGARDavid N. Gill, Board member
- 35SEC EDGARDuane M. Desisto, Board member
- 36SEC EDGARGeorge D. Lemaitre, Board member
- 37SEC EDGARGuido J. Neels, Board member
- 38SEC EDGARLawrence J. Jasinski, Board member
- 39SEC EDGARRyan H. Connelly, Board member
- 40SEC EDGARAaron M. Grossman, General counsel
- 41
- 42
- 43
- 44
- 45
- 46